GenCore version 4.5

OM protein - protein search, using sw model

Run on: August 23, 2002, 14:37:43 ; Search time 30.25 Seconds
(without alignments)
686.638 Million cell updates/sec

Title: US-09-811-118-1
Perfect score: 983
Sequence: 1 MVAATVAAAWLLLWAAACAQ.....VRLQITALVRKLILLKREDL 187

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_032802:*
1: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	983	100.0	187	22	AAB85575	Human glutathione
2	964	98.1	187	21	AAY66677	Membrane-bound pro
3	964	98.1	187	22	AAU29236	Human PRO polypept
4	964	98.1	187	22	AAM38871	Human polypeptide
5	964	98.1	187	22	AAB93154	Human protein sequ
6	964	98.1	187	22	AAB74734	Human secreted pro
7	964	98.1	187	22	AAB65200	Human PRO828 (UNQ4
8	964	98.1	195	22	AAM40657	Human polypeptide
9	964	98.1	196	21	AAB53468	Human colon cancer
10	505	51.4	209	21	AAB18915	A novel polypeptid
11	504	51.3	209	21	AAB24484	Human secreted pro
12	504	51.3	209	22	AAU29258	Human PRO polypept
13	504	51.3	209	22	AAM39735	Human polypeptide
14	504	51.3	217	22	AAM41521	Human polypeptide
15	343	34.9	169	21	AAG20980	Arabidopsis thalia
16	343	34.9	169	21	AAG42765	Arabidopsis thalia
17	343	34.9	214	21	AAG20979	Arabidopsis thalia
18	343	34.9	232	21	AAG42764	Arabidopsis thalia
19	343	34.9	239	21	AAG42763	Arabidopsis thalia
20	340	34.6	169	21	AAG23532	Arabidopsis thalia
21	340	34.6	232	21	AAG23531	Arabidopsis thalia
22	340	34.6	241	21	AAG23530	Arabidopsis thalia
23	334	34.0	169	21	AAG19335	Arabidopsis thalia
24	334	34.0	232	21	AAG19334	Arabidopsis thalia
25	334	34.0	236	21	AAG19333	Arabidopsis thalia
26	331	33.7	233	21	AAG30097	Arabidopsis thalia
27	331	33.7	236	21	AAG30096	Arabidopsis thalia
28	331	33.7	239	21	AAG30095	Arabidopsis thalia
29	329	33.5	167	22	AAU04398	Aloe arborescens P
30	326	33.2	167	22	AAU04515	Aloe vera PHGPx en
31	324	33.0	167	22	AAU04400	Aloe vera PHGPx en
32	321	32.7	167	22	AAU04399	Aloe arborescens P
33	320.5	32.6	169	21	AAG30173	Arabidopsis thalia
34	320.5	32.6	169	21	AAG37608	Arabidopsis thalia
35	320.5	32.6	173	21	AAG27723	Arabidopsis thalia
36	320.5	32.6	193	21	AAG27722	Arabidopsis thalia
37	318	32.3	167	22	AAU04397	Orange phospholipi
38	318	32.3	167	22	AAU04516	Aloe arborescens P
39	317	32.2	149	21	AAY65356	Human 5' EST relat
40	316.5	32.2	173	21	AAG44178	Arabidopsis thalia
41	316.5	32.2	188	21	AAG44177	Arabidopsis thalia
42	315	32.0	167	22	AAU04519	Aloe vera PHGPx mu
43	313	31.8	167	22	AAU04518	Aloe vera PHGPx mu
44	312.5	31.8	166	22	AAU04504	Aloe arborescens S
45	312	31.7	206	21	AAG16584	Arabidopsis thalia

ALIGNMENTS

RESULT 1
AAB85575
ID AAB85575 standard; Protein; 187 AA.
XX
AC AAB85575;
XX
DT 29-OCT-2001 (first entry)
XX
DE Human glutathione peroxidase (GPx6) polypeptide.
XX
KW Glutathione peroxidase; GPx6; anti-human immunodeficiency virus; HIV;
KW antiinflammatory; antiallergic; antiasthmatic; antiatherosclerotic;
KW antianemic; antithyroid; immunosuppressive; antidiabetic; nephrotropic;
KW antigout; neuroprotective; osteopathic; antirheumatic; antiarthritic;
KW tranquilizer; vulnerary; antiarteriosclerotic; hepatotropic; human;
KW antipsoriatic; cytostatic.
XX
OS Homo sapiens.
XX
PN US6231853-B1.
XX
PD 15-MAY-2001.
XX
PF 01-JUN-1998; 98US-0088549.
XX
PR 01-JUN-1998; 98US-0088549.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Hillman JL, Corley NC, Patterson C;
XX
DR WPI; 2001-335067/35.
DR N-PSDB; AAH46980.
XX

```
PT   New substantially purified human glutathione peroxidase polypeptide,
PT   useful for diagnosing, treating or preventing reproductive disorders,
PT   immune disorders and cell proliferative or developmental disorders  -
XX
PS   Claim 1; Fig 1A-C; 26pp; English.
XX
CC   This represents a human glutathione peroxidase (GPx6) polypeptide. The
CC   GPx6 polypeptide is useful for diagnosing, treating or preventing
CC   disorders associated with expression of GPx6, where the disorders are
CC   selected from reproductive disorders, immune disorders such as acquired
CC   immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory
CC   distress syndrome, allergies, asthma, atherosclerosis, anemia, autoimmune
CC   thyroiditis, bronchitis, diabetes mellitus, glomerulonephritis,
CC   Goodpasture's syndrome, gout, multiple sclerosis, myasthenia gravis,
CC   osteoporosis, rheumatoid arthritis, cancer, infections and trauma, and
CC   cell proliferative or development disorders such as arteriosclerosis,
CC   cirrhosis, psoriasis, cancer, Cushing's syndrome, and Syndenham's chorea.
CC   GPx6 is also useful to produce antibodies, and to screen libraries of
CC   pharmaceutical agents to identify those which specifically binds GPx6.
XX
SQ   Sequence   187 AA;


  Query Match            100.0%;  Score 983;  DB 22;  Length 187;
  Best Local Similarity  100.0%;  Pred. No. 7e-103;
  Matches  187;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MVAATVAAAWLLLWAAACAQQEQDFYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mvaatvaaawlllwaaacaqqeqdfydfkavnirgklvslekyrgsvslvvnvasecgft 60

Qy      61 DQHYRALQQLQRDLGPHHFNVLAFPCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAV 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 dqhyralqqlqrdlgphhfnvlafpcnqfgqqepdsnkeiesfacrtysvsfpmfskiav 120

Qy     121 TGTGAHPAFKYLAQTSGKEPTWNFWKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLI 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 tgtgahpafkylaqtsgkeptwnfwkylvapdgkvvgawdptvsveevrlqitalvrkli 180

Qy     181 LLKREDL 187
           |||||||
Db     181 llkredl 187


RESULT   2
AAY66677
ID   AAY66677 standard; protein; 187 AA.
XX
AC   AAY66677;
XX
DT   05-APR-2000  (first entry)
XX
DE   Membrane-bound protein PRO828.
XX
KW   Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW   pharmaceutical; receptor immunoadhesin; gene mapping.
XX
OS   Homo sapiens.
XX
PN   WO9963088-A2.
XX
PD   09-DEC-1999.
XX
PF   02-JUN-1999;   99WO-US12252.
XX
PR   02-JUN-1998;   98US-0087607.
PR   02-JUN-1998;   98US-0087609.
PR   02-JUN-1998;   98US-0087759.
PR   03-JUN-1998;   98US-0087827.
PR   04-JUN-1998;   98US-0088021.
PR   04-JUN-1998;   98US-0088025.
PR   04-JUN-1998;   98US-0088028.
PR   04-JUN-1998;   98US-0088029.
PR   04-JUN-1998;   98US-0088030.
PR   04-JUN-1998;   98US-0088033.
PR   04-JUN-1998;   98US-0088326.
PR   05-JUN-1998;   98US-0088167.
PR   05-JUN-1998;   98US-0088202.
PR   05-JUN-1998;   98US-0088212.
PR   05-JUN-1998;   98US-0088217.
PR   09-JUN-1998;   98US-0088655.
PR   10-JUN-1998;   98US-0088722.
PR   10-JUN-1998;   98US-0088730.
PR   10-JUN-1998;   98US-0088734.
PR   10-JUN-1998;   98US-0088738.
PR   10-JUN-1998;   98US-0088740.
PR   10-JUN-1998;   98US-0088741.
PR   10-JUN-1998;   98US-0088742.
PR   10-JUN-1998;   98US-0088810.
PR   10-JUN-1998;   98US-0088811.
PR   10-JUN-1998;   98US-0088824.
PR   10-JUN-1998;   98US-0088825.
PR   10-JUN-1998;   98US-0088826.
PR   11-JUN-1998;   98US-0088858.
PR   11-JUN-1998;   98US-0088861.
PR   11-JUN-1998;   98US-0088863.
PR   11-JUN-1998;   98US-0088876.
PR   12-JUN-1998;   98US-0089090.
PR   12-JUN-1998;   98US-0089105.
PR   16-JUN-1998;   98US-0089440.
PR   16-JUN-1998;   98US-0089512.
PR   16-JUN-1998;   98US-0089514.
PR   17-JUN-1998;   98US-0089532.
PR   17-JUN-1998;   98US-0089538.
PR   17-JUN-1998;   98US-0089598.
PR   17-JUN-1998;   98US-0089599.
PR   17-JUN-1998;   98US-0089600.
PR   17-JUN-1998;   98US-0089653.
PR   18-JUN-1998;   98US-0089801.
PR   18-JUN-1998;   98US-0089907.
PR   18-JUN-1998;   98US-0089908.
PR   19-JUN-1998;   98US-0089947.
PR   19-JUN-1998;   98US-0089948.
PR   19-JUN-1998;   98US-0089952.
PR   22-JUN-1998;   98US-0090246.
PR   22-JUN-1998;   98US-0090252.
PR   22-JUN-1998;   98US-0090254.
PR   23-JUN-1998;   98US-0090349.
PR   23-JUN-1998;   98US-0090355.
PR   24-JUN-1998;   98US-0090429.
PR   24-JUN-1998;   98US-0090431.
PR   24-JUN-1998;   98US-0090435.
PR   24-JUN-1998;   98US-0090444.
PR   24-JUN-1998;   98US-0090445.
PR   24-JUN-1998;   98US-0090461.
PR   24-JUN-1998;   98US-0090472.
PR   24-JUN-1998;   98US-0090535.
PR   24-JUN-1998;   98US-0090538.
PR   24-JUN-1998;   98US-0090540.
PR   24-JUN-1998;   98US-0090557.
PR   25-JUN-1998;   98US-0090676.
PR   25-JUN-1998;   98US-0090678.
PR   25-JUN-1998;   98US-0090688.
PR   25-JUN-1998;   98US-0090690.
PR   25-JUN-1998;   98US-0090691.
PR   25-JUN-1998;   98US-0090694.
PR   25-JUN-1998;   98US-0090695.
PR   25-JUN-1998;   98US-0090696.
PR   26-JUN-1998;   98US-0090862.
PR   26-JUN-1998;   98US-0090863.
PR   01-JUL-1998;   98US-0091358.
PR   01-JUL-1998;   98US-0091360.
PR   01-JUL-1998;   98US-0091544.
PR   02-JUL-1998;   98US-0091478.
PR   02-JUL-1998;   98US-0091486.
PR   02-JUL-1998;   98US-0091519.
```

```
PR   02-JUL-1998;   98US-0091626.
PR   02-JUL-1998;   98US-0091628.
PR   02-JUL-1998;   98US-0091633.
PR   02-JUL-1998;   98US-0091646.
PR   02-JUL-1998;   98US-0091673.
PR   07-JUL-1998;   98US-0091978.
PR   07-JUL-1998;   98US-0091982.
PR   09-JUL-1998;   98US-0092182.
PR   10-JUL-1998;   98US-0092472.
PR   20-JUL-1998;   98US-0093339.
PR   30-JUL-1998;   98US-0094651.
PR   04-AUG-1998;   98US-0095282.
PR   04-AUG-1998;   98US-0095285.
PR   04-AUG-1998;   98US-0095301.
PR   04-AUG-1998;   98US-0095302.
PR   04-AUG-1998;   98US-0095318.
PR   04-AUG-1998;   98US-0095321.
PR   04-AUG-1998;   98US-0095325.
PR   10-AUG-1998;   98US-0095916.
PR   10-AUG-1998;   98US-0095929.
PR   10-AUG-1998;   98US-0096012.
PR   11-AUG-1998;   98US-0096143.
PR   11-AUG-1998;   98US-0096146.
PR   12-AUG-1998;   98US-0096329.
PR   17-AUG-1998;   98US-0096757.
PR   17-AUG-1998;   98US-0096766.
PR   17-AUG-1998;   98US-0096768.
PR   17-AUG-1998;   98US-0096773.
PR   17-AUG-1998;   98US-0096791.
PR   17-AUG-1998;   98US-0096867.
PR   17-AUG-1998;   98US-0096891.
PR   17-AUG-1998;   98US-0096894.
PR   17-AUG-1998;   98US-0096895.
PR   17-AUG-1998;   98US-0096897.
PR   18-AUG-1998;   98US-0096949.
PR   18-AUG-1998;   98US-0096950.
PR   18-AUG-1998;   98US-0096959.
PR   18-AUG-1998;   98US-0096960.
PR   18-AUG-1998;   98US-0097022.
PR   19-AUG-1998;   98US-0097141.
PR   20-AUG-1998;   98US-0097218.
PR   24-AUG-1998;   98US-0097661.
PR   26-AUG-1998;   98US-0097951.
PR   26-AUG-1998;   98US-0097952.
PR   26-AUG-1998;   98US-0097954.
PR   26-AUG-1998;   98US-0097955.
PR   26-AUG-1998;   98US-0097971.
PR   26-AUG-1998;   98US-0097974.
PR   26-AUG-1998;   98US-0097978.
PR   26-AUG-1998;   98US-0097979.
PR   26-AUG-1998;   98US-0097986.
PR   26-AUG-1998;   98US-0098014.
PR   31-AUG-1998;   98US-0098525.
PR   16-SEP-1998;   98US-0100634.
PR   12-JAN-1999;   99US-0115565.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker K,  Chen J,  Goddard A,  Gurney AL,  Smith V,  Watanabe CK;
PI   Wood WI,  Yuan J;
XX
DR   WPI; 2000-072883/06.
DR   N-PSDB; AAZ65013.
XX
PT   Membrane-bound proteins and related nucleotide sequences  -
XX
PS   claim 12; Fig 120; 822pp; English.
XX
CC   The invention provides membrane-bound PRO polypeptides and
CC   polynucleotides encoding them. The PRO sequences of the invention were
CC   identified based on extracellular domain homology screening. The PRO
CC   sequences have homology with proteins including LDL receptors, TIE
CC   ligands and various enzymes. The membrane-bound proteins and receptor
CC   molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC   immunoadhesins, for instance, can be used as therapeutic agents to block
CC   receptor-ligand interactions. The membrane-bound proteins can also be
CC   employed for screening of potential peptide or small molecule inhibitors
CC   of the relevant receptor/ligand interaction. The PRO encoding sequences
CC   are useful as hybridization probes, in chromosome and gene mapping and in
CC   the generation of antisense RNA and DNA. PRO nucleic acid sequences
CC   will also be useful for the preparation of PRO polypeptides, especially
CC   by recombinant techniques.
XX
SQ   Sequence   187 AA;


  Query Match             98.1%;  Score 964;  DB 21;  Length 187;
  Best Local Similarity   98.9%;  Pred. No. 9.8e-101;
  Matches  185;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 MVAATVAAAWLLLWAAACAQQEQDFYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFT 60
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mvaatvaaawlllwaaacaqqeqdfydfkavnirgklvslekyrgsvslvvnvasecgft 60

Qy      61 DQHYRALQQLQRDLGPHHFNVLAFPCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAV 120
           |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db      61 dqhyralqqlqrdlgphhfnvlafpcnqfgqqepdsnkeiesfarrtysvsfpmfskiav 120

Qy     121 TGTGAHPAFKYLAQTSGKEPTWNFWKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLI 180
           |||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||
Db     121 tgtgahpafkylaqtsgkeptwnfwkylvapdgkvvgawdptvsveevrpqitalvrkli 180

Qy     181 LLKREDL 187
           |||||||
Db     181 llkredl 187


RESULT   3
AAU29236
ID   AAU29236 standard; Protein; 187 AA.
XX
AC   AAU29236;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human PRO polypeptide sequence #213.
XX
KW   PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
KW   dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW   blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW   adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200168848-A2.
XX
PD   20-SEP-2001.
XX
PF   28-FEB-2001; 2001WO-US06520.
XX
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05841.
PR   03-MAR-2000; 2000US-187202P.
PR   06-MAR-2000; 2000US-186968P.
PR   14-MAR-2000; 2000US-189320P.
PR   14-MAR-2000; 2000US-189328P.
PR   15-MAR-2000; 2000WO-US06884.
PR   21-MAR-2000; 2000US-190828P.
PR   21-MAR-2000; 2000US-191007P.
PR   21-MAR-2000; 2000US-191048P.
PR   21-MAR-2000; 2000US-191314P.
PR   28-MAR-2000; 2000US-192655P.
PR   29-MAR-2000; 2000US-193032P.
PR   29-MAR-2000; 2000US-193053P.
PR   30-MAR-2000; 2000WO-US08439.
PR   04-APR-2000; 2000US-194449P.
```

PR 04-APR-2000; 2000US-194647P.
PR 11-APR-2000; 2000US-195975P.
PR 11-APR-2000; 2000US-196000P.
PR 11-APR-2000; 2000US-196187P.
PR 11-APR-2000; 2000US-196690P.
PR 11-APR-2000; 2000US-196820P.
PR 18-APR-2000; 2000US-198121P.
PR 18-APR-2000; 2000US-198585P.
PR 25-APR-2000; 2000US-199397P.
PR 25-APR-2000; 2000US-199550P.
PR 25-APR-2000; 2000US-199654P.
PR 03-MAY-2000; 2000US-201516P.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 05-JUN-2000; 2000US-209832P.
PR 28-JUL-2000; 2000WO-US20710.
PR 22-AUG-2000; 2000US-0644848.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2001-602746/68.
DR N-PSDB; AAS46137.
XX
PT Novel nucleic acids encoding PRO polypeptides, used to diagnose the
PT presence of tumours, such as prostate and breast tumours, in mammals and
PT to screen for modulators of the compounds -
XX
PS Claim 11; Fig 426; 774pp; English.
XX
CC Sequences AAU29024-AAU29328 represent PRO polypeptides of the invention.
CC The PRO polypeptides and their associated nucleic acids can be used to
CC detect the presence of a tumour in a mammal by comparing the level of
CC expression of a PRO polypeptide in a test sample of cells from the animal
CC and a control sample of normal cells, whereby a higher level of
CC expression in the test sample indicates the presence of a tumour in the
CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats
CC and rabbits but are preferably human. The polypeptides can be used to
CC stimulate tumour necrosis factor (TNF) alpha release from human blood,
CC when contacted with it. A specific polypeptide can be used to stimulate
CC the proliferation or differentiation of chondrocyte cells. The PRO
CC proteins can be used to determine the presence of tumours and also
CC susceptibility to tumour development, particularly adrenal, lung, colon,
CC breast, prostate, rectal, cervical, or liver tumours, in mammalian
CC subjects. The oligonucleotide probes specific for the PRO nucleic acids
CC can be used for genetic analysis of individuals with genetic disorders.
XX
SQ Sequence 187 AA;

Query Match 98.1%; Score 964; DB 22; Length 187;
Best Local Similarity 98.9%; Pred. No. 9.8e-101;
Matches 185; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy      1 MVAATVAAAWLLLWAAACAQQEQDFYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 mvaatvaaawlllwaaacaqqeqdfydfkavnirgklvslekyrgsvslvvnvasecgft 60

Qy     61 DQHYRALQQLQRDLGPHHFNVLAFPCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAV 120
          |||||||||||||||||||||||||||||||||||| ||||||||||||||||
Db     61 dqhyralqqlqrdlgphhfnvlafpcnqfgqqepdsnkeiesfarrtysvsfpmfskiav 120

Qy    121 TGTGAHPAFKYLAQTSGKEPTWNFWKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLI 180
          |||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db    121 tgtgahpafkylaqtsgkeptwnfwkylvapdgkvvgawdptvsveevrpqitalvrkli 180

Qy    181 LLKREDL 187
          |||||||
Db    181 llkredl 187
```

RESULT 4
AAM38871
ID AAM38871 standard; Protein; 187 AA.
XX
AC AAM38871;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 2016.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI58027.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 3; SEQ ID NO 2016; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 187 AA;

```
  Query Match             98.1%;  Score 964;  DB 22;  Length 187;
  Best Local Similarity   98.9%;  Pred. No. 9.8e-101;
  Matches  185;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy      1 MVAATVAAAWLLLWAAACAQQEQDFYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 mvaatvaaawlllwaaacaqqeqdfydfkavnirgklvslekyrgsvslvvnvasecgft 60

Qy     61 DQHYRALQQLQRDLGPHHFNVLAFPCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAV 120
          |||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||
Db     61 dqhyralqqlqrdlgphhfnvlafpcnqfgqqepdsnkeiesfarrtysvsfpmfskiav 120

Qy    121 TGTGAHPAFKYLAQTSGKEPTWNFWKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLI 180
          |||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db    121 tgtgahpafkylaqtsgkeptwnfwkylvapdgkvvgawdptvsveevrpqitalvrkli 180

Qy    181 LLKREDL 187
          |||||||
Db    181 llkredl 187


RESULT   5
AAB93154
ID   AAB93154 standard; Protein; 187 AA.
XX
AC   AAB93154;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human protein sequence SEQ ID NO:12071.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000; 2000JP-0118776.
PR   02-MAY-2000; 2000JP-0183767.
PR   09-JUN-2000; 2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 8; SEQ ID 12071; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence   187 AA;


  Query Match             98.1%;  Score 964;  DB 22;  Length 187;
  Best Local Similarity   98.9%;  Pred. No. 9.8e-101;
  Matches  185;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy      1 MVAATVAAAWLLLWAAACAQQEQDFYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 mvaatvaaawlllwaaacaqqeqdfydfkavnirgklvslekyrgsvslvvnvasecgft 60

Qy     61 DQHYRALQQLQRDLGPHHFNVLAFPCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAV 120
          |||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||
Db     61 dqhyralqqlqrdlgphhfnvlafpcnqfgqqepdsnkeiesfarrtysvsfpmfskiav 120

Qy    121 TGTGAHPAFKYLAQTSGKEPTWNFWKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLI 180
          |||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db    121 tgtgahpafkylaqtsgkeptwnfwkylvapdgkvvgawdptvsveevrpqitalvrkli 180

Qy    181 LLKREDL 187
          |||||||
Db    181 llkredl 187


RESULT   6
AAB74734
ID   AAB74734 standard; Protein; 187 AA.
XX
AC   AAB74734;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Human secreted protein sequence encoded by gene 2 SEQ ID NO:43.
XX
KW   Human; secreted protein; diagnosis; immunomodulatory; antisclerotic;
KW   dermatological; immunosuppressive; antiinflammatory; anti-HIV;
KW   immunostimulant; cytostatic; cardiant; vascular; anti-angiogenic;
KW   ophthalmological; neuroprotectant; nootropic; anticonvulsant; vaccine;
KW   antialzheimer; antiparkinsonian; antimicrobial; vulnerary; gene therapy;
KW   immune disorder; hyperproliferative disorder; cardiovascular disease;
KW   cancer; angiogenic disorder; neurological disorder; infectious disease;
KW   wound healing; regeneration; chemotaxis.
XX
OS   Homo sapiens.
XX
PN   WO200112775-A2.
XX
PD   22-FEB-2001.
XX
PF   16-AUG-2000; 2000WO-US22325.
XX
PR   17-AUG-1999;   99US-0149182.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ni J,  Florence KA,  Fiscella M,  Wei P,  Baker KP;
PI   Birse CE,  Young PE,  Komatsoulis GA,  Moore PA,  Soppet DR;
XX
DR   WPI; 2001-147550/15.
DR   N-PSDB; AAF81788.
XX
```

```
PT   Nucleic acids encoding 25 human secreted polypeptides, useful for
PT   preventing, diagnosing and/or treating e.g. cancers, Parkinson's
PT   disease and diabetic retinopathy -
XX
PS   Claim 11; Page 462; 485pp; English.
XX
CC   AAF81787 to AAF81817 encode the human secreted proteins given in AAB74733
CC   to AAB74772. Human secreted proteins can have activities based on the
CC   tissues and cells they are expressed in. Example of activities include:
CC   immunomodulatory; antisclerotic; dermatological; immunosuppressive;
CC   antiinflammatory; anti-HIV; immunostimulant; cytostatic; cardiant;
CC   vascular; anti-angiogenic; ophthalmological; neuroprotectant; nootropic;
CC   anticonvulsant; antialzheimers; antiparkinsonian; antimicrobial; and
CC   vulnerary. Human secreted proteins can be used in gene therapy and
CC   vaccine. Human secreted protein nucleotide sequences (NAM1) and proteins
CC   (PEP1) may be used in the prevention, diagnosis and treatment of diseases
CC   associated with inappropriate polypeptide expression. For example, NAM1
CC   and PEP1 may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patients genome
CC   that affect the activity of proteins by expressing inactive proteins or
CC   to supplement the patients own production of polypeptides. Disorders that
CC   may be prevented, diagnosed and/or treated include immune disorders,
CC   hyperproliferative disorders (e.g. cancers), cardiovascular diseases,
CC   angiogenic disorders, neurological disorders, infectious diseases and/or
CC   for promoting wound healing, regeneration and /or chemotaxis. AAF81778 to
CC   AAF81786 and AAB74732 represent sequences used in the exemplification of
CC   the present invention.
XX
SQ   Sequence   187 AA;


  Query Match            98.1%;  Score 964;  DB 22;  Length 187;
  Best Local Similarity  98.9%;  Pred. No. 9.8e-101;
  Matches  185;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 MVAATVAAAWLLLWAAACAQQEQDFYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mvaatvaaawlllwaaacaqqeqdfydfkavnirgklvslekyrgsvslvvnvasecgft 60

Qy      61 DQHYRALQQLQRDLGPHHFNVLAFPCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAV 120
           |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db      61 dqhyralqqlqrdlgphhfnvlafpcnqfgqqepdsnkeiesfarrtysvsfpmfskiav 120

Qy     121 TGTGAHPAFKYLAQTSGKEPTWNFWKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLI 180
           |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db     121 tgtgahpafkylaqtsgkeptwnfwkylvapdgkvvgawdptvsveevrpqitalvrkli 180

Qy     181 LLKREDL 187
           |||||||
Db     181 llkredl 187


RESULT   7
AAB65200
ID   AAB65200 standard; Protein; 187 AA.
XX
AC   AAB65200;
XX
DT   02-APR-2001  (first entry)
XX
DE   Human PRO828 (UNQ469) protein sequence SEQ ID NO:189.
XX
KW   Human; secreted and transmembrane protein; PRO; cytostatic;
KW   cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
KW   diagnostic assay.
XX
OS   Homo sapiens.
XX
PN   WO200073454-A1.
XX
PD   07-DEC-2000.
XX
PF   30-MAR-2000; 2000WO-US08439.
XX
PR   02-JUN-1999;   99WO-US12252.
PR   23-JUN-1999;   99US-0141037.
PR   07-JUL-1999;   99US-0143048.
PR   20-JUL-1999;   99US-0144758.
PR   26-JUL-1999;   99US-0145698.
PR   28-JUL-1999;   99US-0146222.
PR   17-AUG-1999;   99US-0149396.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   08-OCT-1999;   99US-0158663.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   02-MAR-2000; 2000WO-US05841.
PR   15-MAR-2000; 2000WO-US06884.
PR   20-MAR-2000; 2000WO-US07377.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi CJ,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2001-032160/04.
DR   N-PSDB; AAF44159.
XX
PT   PRO polynucleotides used to produce polypeptides used to target
PT   bioactive molecules such as toxins, radiolabels or antibodies, to
PT   specific cells, to cause targeted cell death -
XX
PS   Claim 12; Fig 120; 935pp; English.
XX
CC   The present invention describes human secreted and transmembrane PRO
CC   proteins. The PRO proteins have cytostatic activity. The PRO proteins
CC   can be used for targeted delivery of bioactive molecules, such as
CC   toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
CC   sequences, and their fragments, can be used as hybridisation probes, in
CC   chromosomal and gene mapping, and in the generation of anti-sense RNA
CC   and DNA. They may also be used to produce transgenic animals which are
CC   used to develop and screen therapeutically useful reagents. The PRO
CC   nucleotide and protein sequence can be used for tissue typing and in
CC   treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
CC   AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
CC   in the isolation of human PRO sequences. AAF44087 to AAF44269 and
CC   AAB65154 to AAB65300 represent human PRO polynucleotide and protein
CC   sequences given in the exemplification of the present invention.
XX
SQ   Sequence   187 AA;


  Query Match            98.1%;  Score 964;  DB 22;  Length 187;
  Best Local Similarity  98.9%;  Pred. No. 9.8e-101;
  Matches  185;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 MVAATVAAAWLLLWAAACAQQEQDFYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mvaatvaaawlllwaaacaqqeqdfydfkavnirgklvslekyrgsvslvvnvasecgft 60

Qy      61 DQHYRALQQLQRDLGPHHFNVLAFPCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAV 120
           |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db      61 dqhyralqqlqrdlgphhfnvlafpcnqfgqqepdsnkeiesfarrtysvsfpmfskiav 120
```

```
Qy    121 TGTGAHPAFKYLAQTSGKEPTWNFWKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLI 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db    121 tgtgahpafkylaqtsgkeptwnfwkylvapdgkvvgawdptvsveevrpqitalvrkli 180

Qy    181 LLKREDL 187
          |||||||
Db    181 llkredl 187


RESULT   8
AAM40657
ID   AAM40657 standard; Protein; 195 AA.
XX
AC   AAM40657;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polypeptide SEQ ID NO 5588.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
PR   14-SEP-2000; 2000US-0662191.
PR   19-OCT-2000; 2000US-0693036.
PR   29-NOV-2000; 2000US-0727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   N-PSDB; AAI59813.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Example 2; SEQ ID NO 5588; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence   195 AA;


  Query Match             98.1%;  Score 964;  DB 22;  Length 195;
  Best Local Similarity   98.9%;  Pred. No. 1e-100;
  Matches  185;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy      1 MVAATVAAAWLLLWAAACAQQEQDFYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      9 mvaatvaaawlllwaaacaqqeqdfydfkavnirgklvslekyrgsvslvvnvasecgft 68

Qy     61 DQHYRALQQLQRDLGPHHFNVLAFPCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAV 120
          |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||
Db     69 dqhyralqqlqrdlgphhfnvlafpcnqfgqqepdsnkeiesfarrtysvsfpmfskiav 128

Qy    121 TGTGAHPAFKYLAQTSGKEPTWNFWKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLI 180
          |||||||||||||||||||||||||||||||||||||||||||| ||||||||| ||||||
Db    129 tgtgahpafkylaqtsgkeptwnfwkylvapdgkvvgawdptvsveevrpqitalvrkli 188

Qy    181 LLKREDL 187
          |||||||
Db    189 llkredl 195


RESULT   9
AAB53468
ID   AAB53468 standard; Protein; 196 AA.
XX
AC   AAB53468;
XX
DT   09-MAR-2001  (first entry)
XX
DE   Human colon cancer antigen protein sequence SEQ ID NO:1008.
XX
KW   Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW   identification; cytostatic; cardioactive; neuroprotective; vulnerary;
KW   immunomodulatory; muscular; gynaecological; gastrointestinal;
KW   nephrotropic; antiinfective; antibacterial; gene therapy; wound;
KW   neural disorder; immune system disorder; muscular disorder;
KW   reproductive disorder; gastrointestinal disorder; renal disorder;
KW   infectious disease; cardiovascular disorder.
XX
OS   Homo sapiens.
XX
PN   WO200055351-A1.
XX
PD   21-SEP-2000.
XX
PF   08-MAR-2000; 2000WO-US05883.
XX
PR   12-MAR-1999;   99US-0124270.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM;
XX
DR   WPI; 2000-587534/55.
DR   N-PSDB; AAC98225.
XX
PT   Colon cancer associated gene sequences, referred to as colon cancer
PT   antigens, useful for the treatment, prevention, and diagnosis of colon
PT   disorders such as colon cancer -
XX
PS   Claim 11; Page 1592; 2104pp; English.
XX
CC   AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC   called human colon cancer antigens, given in AAB53234 to AAB54006. The
CC   human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC   neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC   vulnerary, nephrotropic, antiinfective and antibacterial activities, and
CC   can be used in gene therapy. The colon cancer antigen polynucleotides,
CC   proteins and antibodies to the proteins are useful for the prevention,
```

```
CC   treatment and diagnosis of colon disorders, such as colon cancer. The
CC   polynucleotides may be used in diagnostics and research, such as for
CC   chromosome identification, and as hybridisation probes. The proteins
CC   may also be used to prevent diseases such as neural disorders, immune
CC   system disorders, muscular disorders, reproductive disorders,
CC   gastrointestinal disorders, wounds, renal disorders, infectious
CC   diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC   AAB54007 represent sequences used in the exemplification of the present
CC   invention.
XX
SQ   Sequence   196 AA;


  Query Match             98.1%;  Score 964;  DB 21;  Length 196;
  Best Local Similarity   98.9%;  Pred. No. 1.1e-100;
  Matches  185;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 MVAATVAAAWLLLWAAACAQQEQDFYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      10 mvaatvaaawlllwaaacaqqeqdfydfkavnirgklvslekyrgsvslvvnvasecgft 69

Qy      61 DQHYRALQQLQRDLGPHHFNVLAFPCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAV 120
           ||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db      70 dqhyralqqlqrdlgphhfnvlafpcnqfgqqepdsnkeiesfarrtysvsfpmfskiav 129

Qy     121 TGTGAHPAFKYLAQTSGKEPTWNFWKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLI 180
           |||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||
Db     130 tgtgahpafkylaqtsgkeptwnfwkylvapdgkvvgawdptvsveevrpqitalvrkli 189

Qy     181 LLKREDL 187
           |||||||
Db     190 llkredl 196


RESULT  10
AAB18915
ID   AAB18915 standard; Protein; 209 AA.
XX
AC   AAB18915;
XX
DT   08-FEB-2001  (first entry)
XX
DE   A novel polypeptide designated PRO1785.
XX
KW   Secreted protein; transmembrane protein; PRO1484; PRO4334; PRO1122;
KW   PRO1889; PRO1890; PRO1887; PRO1785; PRO4353; PRO4357; PRO4405; PRO4356;
KW   PRO4352; PRO4380; PRO4354; PRO4408; PRO5737; PRO4425; PRO5990; PRO6030;
KW   PRO4424; PRO4422; PRO4430; PRO4499; tumour; obesity; diabetes;
KW   insulinemia; kidney disorder; Bergers disease; nephropathy;
KW   Schonlein-Henoch purpura; celiac disease; dermatitis herpetiformis;
KW   Crohns disease.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..31
FT                   /note= "signal peptide"
FT   Misc-difference 118
FT                   /note= "Asp encoded by CCA"
XX
PN   WO200056889-A2.
XX
PD   28-SEP-2000.
XX
PF   01-MAR-2000; 2000WO-US05601.
XX
PR   23-MAR-1999;   99US-0125774.
PR   23-MAR-1999;   99US-0125778.
PR   24-MAR-1999;   99US-0125826.
PR   31-MAR-1999;   99US-0127035.
PR   05-APR-1999;   99US-0127706.
PR   21-APR-1999;   99US-0130359.
PR   27-APR-1999;   99US-0131270.
PR   27-APR-1999;   99US-0131272.
PR   27-APR-1999;   99US-0131291.
PR   04-MAY-1999;   99US-0132371.
PR   04-MAY-1999;   99US-0132379.
PR   04-MAY-1999;   99US-0132383.
PR   25-MAY-1999;   99US-0135750.
PR   08-JUN-1999;   99US-0138166.
PR   20-JUL-1999;   99US-0144791.
PR   03-AUG-1999;   99US-0146970.
PR   09-DEC-1999;   99US-0170262.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Desnoyers L,  Eaton DL,  Goddard A,  Godowski PJ,  Gurney AL,  Pan J;
PI   Stewart TA,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2000-628263/60.
DR   N-PSDB; AAA96342.
XX
PT   Novel secreted and transmembrane polypeptides useful for diagnosing
PT   tumour in a mammal, for identifying agonists and antagonists of the
PT   polypeptide and for therapeutic use
XX
PS   Claim 12; Fig 14; 222pp; English.
XX
CC   The present sequence represents a secreted or transmembrane polypeptide.
CC   The specification describes polypeptides designated PRO1484, PRO4334,
CC   PRO1122, PRO1889, PRO1890, PRO1887, PRO1785, PRO4353, PRO4357, PRO4405,
CC   PRO4356, PRO4352, PRO4380, PRO4354, PRO4408, PRO5737, PRO4425, PRO5990,
CC   PRO6030, PRO4424, PRO4422, PRO4430 and PRO4499. PRO1889 polypeptide is
CC   useful for diagnosing tumour in a mammal. The polypeptides, their
CC   agonists and antagonists are useful treating a condition associated with
CC   expression or activity of the polypeptide. Conditions treated include
CC   obesity, diabetes or hyper-or hypo-insulinemia. The polypeptides are
CC   capable of inducing proliferation of mammalian kidney mesangial cells
CC   and are therefore useful for treating kidney disorders associated with
CC   decreased mesangial cell function such as Bergers disease or other
CC   nephropathies associated with Schonlein-Henoch purpura, celiac disease,
CC   dermatitis herpetiformis or Crohns disease. The nucleic acids may be used
CC   to generate transgenic animals for use in development and screening of
CC   therapeutically useful reagents and also for chromosome identification
CC   and tissue typing.
XX
SQ   Sequence   209 AA;


  Query Match             51.4%;  Score 505;  DB 21;  Length 209;
  Best Local Similarity   55.2%;  Pred. No. 9.5e-49;
  Matches   90;  Conservative   32;  Mismatches   41;  Indels    0;  Gaps    0;

Qy      25 FYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFTDQHYRALQQLQRDLGPHHFNVLAF 84
           || |:  : :|: |||||:| |||||||||:|  ||::|  |::| :: || ||:||||
Db      47 fyafevkdakgrtvslekykgkvslvvnvasdcqltdrnylglkelhkefgpshfsvlaf 106

Qy      85 PCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAVTGTGAHPAFKYLAQTSGKEPTWNF 144
           ||||||: ||  :||:|||| : | |:||:| || : |:   |||::|  :| ||| |||
Db     107 pcnqfgeseprdskevesfarknygvtfpifhkikilgsegepafrflvdsskkeprwnf 166

Qy     145 WKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLILLKREDL 187
           ||||| |:|:||  | |   :| :|  | ||||::|: |:|||
Db     167 wkylvnpegqvvkfwrpeepievirpdiaalvrqviikkkedl 209


RESULT  11
AAB24484
ID   AAB24484 standard; Protein; 209 AA.
XX
AC   AAB24484;
XX
DT   20-NOV-2000  (first entry)
XX
DE   Human secreted protein sequence encoded by gene 16 SEQ ID NO:109.
XX
```

```
KW   Human; secreted protein; cytostatic; antianaemic; antidiabetic;
KW   antiinflammatory; ophthalmological; antirheumatic; antiarthritic;
KW   antipsoriatic; antiangiogenic; cardiant; anti-HIV; nootropic;
KW   neuroprotective; antimicrobial; antiparkinsonian; cancer;
KW   immune system disorder; angiogenesis; hyperproliferative disorder;
KW   cardiovascular disorder; apoptosis; neurological disease;
KW   infectious disease; wound healing; chromosome 5.
XX
OS   Homo sapiens.
XX
PN   WO200035937-A1.
XX
PD   22-JUN-2000.
XX
PF   16-DEC-1999;   99WO-US29950.
XX
PR   17-DEC-1998;   98US-0112809.
PR   18-DEC-1998;   98US-0113006.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Ebner R,  Rosen CA,  Endress GA,  Soppet DR,  Ni J;
PI   Duan DR,  Moore PA,  Shi Y,  Lafleur DW,  Olsen HS,  Florence K;
XX
DR   WPI; 2000-431566/37.
DR   N-PSDB; AAA78428.
XX
PT   Forty seven human nucleic acids encoding secreted proteins, useful in
PT   the treatment, prevention and diagnosis of cancers, disorders of the
PT   immune system, angiogenesis disorders, neurological diseases and
PT   hyperproliferative disorders -
XX
PS   Claim 11; Page 523-524; 562pp; English.
XX
CC   The polynucleotide sequence given in AAA78381 to AAA78432 encode the
CC   human secreted proteins given in AAB24437 to AAB24604. Human secreted
CC   proteins have activities based on the tissues and cells the genes are
CC   expressed in. Examples of activities include: cytostatic; antianaemic;
CC   antidiabetic; antiinflammatory; ophthalmological; antirheumatic;
CC   antiarthritic; antipsoriatic; antiangiogenic; cardiant; anti-HIV;
CC   nootropic; neuroprotective; antimicrobial and antiparkinsonian.
CC   Human secreted protein polynucleotides, polypeptides, antagonists and/or
CC   agonists may be useful in treating, preventing, and/or diagnosing other
CC   diseases, disorders, and/or conditions such as: (a) cancers; (b)
CC   disorders of the immune system; (c) angiogenesis disorders; (d)
CC   hyperproliferative disorders; (e) cardiovascular disorders; (f) diseases
CC   associated with increase apoptosis; (g) neurological diseases; and
CC   (h) infectious diseases. They are also used to promote wound healing.
CC   AAA78372 to AAA78380 and AAB24436 represent sequences used in the
CC   exemplification of the present invention.
XX
SQ   Sequence   209 AA;


  Query Match             51.3%;  Score 504;  DB 21;  Length 209;
  Best Local Similarity   55.2%;  Pred. No. 1.2e-48;
  Matches   90;  Conservative   32;  Mismatches   41;  Indels    0;  Gaps    0;

Qy      25 FYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFTDQHYRALQQLQRDLGPHHFNVLAF 84
           || |:  : :|: ||||||:| ||||||||||:|  ||::|  |::| :: || ||:||||
Db      47 fyafevkdakgrtvslekykgkvslvvnvasdcqltdrnylglkelhkefgpshfsvlaf 106

Qy      85 PCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAVTGTGAHPAFKYLAQTSGKEPTWNF 144
           ||||||: ||  :||:|||| : | |:||:| || : |:   |||::|  :| ||| |||
Db     107 pcnqfgeseprpskevesfarknygvtfpifhkikilgsegepafrflvdsskkeprwnf 166

Qy     145 WKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLILLKREDL 187
           ||||| |:|:||  | |   :| :|  | ||||::|: |:|||
Db     167 wkylvnpegqvvkfwrpeepievirpdiaalvrqviikkkedl 209


RESULT  12
AAU29258
ID   AAU29258 standard; Protein; 209 AA.
XX
AC   AAU29258;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human PRO polypeptide sequence #235.
XX
KW   PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
KW   dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW   blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW   adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200168848-A2.
XX
PD   20-SEP-2001.
XX
PF   28-FEB-2001; 2001WO-US06520.
XX
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05841.
PR   03-MAR-2000; 2000US-187202P.
PR   06-MAR-2000; 2000US-186968P.
PR   14-MAR-2000; 2000US-189320P.
PR   14-MAR-2000; 2000US-189328P.
PR   15-MAR-2000; 2000WO-US06884.
PR   21-MAR-2000; 2000US-190828P.
PR   21-MAR-2000; 2000US-191007P.
PR   21-MAR-2000; 2000US-191048P.
PR   21-MAR-2000; 2000US-191314P.
PR   28-MAR-2000; 2000US-192655P.
PR   29-MAR-2000; 2000US-193032P.
PR   29-MAR-2000; 2000US-193053P.
PR   30-MAR-2000; 2000WO-US08439.
PR   04-APR-2000; 2000US-194449P.
PR   04-APR-2000; 2000US-194647P.
PR   11-APR-2000; 2000US-195975P.
PR   11-APR-2000; 2000US-196000P.
PR   11-APR-2000; 2000US-196187P.
PR   11-APR-2000; 2000US-196690P.
PR   11-APR-2000; 2000US-196820P.
PR   18-APR-2000; 2000US-198121P.
PR   18-APR-2000; 2000US-198585P.
PR   25-APR-2000; 2000US-199397P.
PR   25-APR-2000; 2000US-199550P.
PR   25-APR-2000; 2000US-199654P.
PR   03-MAY-2000; 2000US-201516P.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   05-JUN-2000; 2000US-209832P.
PR   28-JUL-2000; 2000WO-US20710.
PR   22-AUG-2000; 2000US-0644848.
PR   24-AUG-2000; 2000WO-US23328.
PR   08-NOV-2000; 2000WO-US30952.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000WO-US34956.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Chen J,  Desnoyers L,  Goddard A,  Godowski PJ,  Gurney AL;
PI   Pan J,  Smith V,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2001-602746/68.
DR   N-PSDB; AAS46159.
XX
PT   Novel nucleic acids encoding PRO polypeptides, used to diagnose the
PT   presence of tumours, such as prostate and breast tumours, in mammals and
PT   to screen for modulators of the compounds -
XX
```

PS Claim 11; Fig 470; 774pp; English.
XX
CC Sequences AAU29024-AAU29328 represent PRO polypeptides of the invention.
CC The PRO polypeptides and their associated nucleic acids can be used to
CC detect the presence of a tumour in a mammal by comparing the level of
CC expression of a PRO polypeptide in a test sample of cells from the animal
CC and a control sample of normal cells, whereby a higher level of
CC expression in the test sample indicates the presence of a tumour in the
CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats
CC and rabbits but are preferably human. The polypeptides can be used to
CC stimulate tumour necrosis factor (TNF) alpha release from human blood,
CC when contacted with it. A specific polypeptide can be used to stimulate
CC the proliferation or differentiation of chondrocyte cells. The PRO
CC proteins can be used to determine the presence of tumours and also
CC susceptibility to tumour development, particularly adrenal, lung, colon,
CC breast, prostate, rectal, cervical, or liver tumours, in mammalian
CC subjects. The oligonucleotide probes specific for the PRO nucleic acids
CC can be used for genetic analysis of individuals with genetic disorders.
XX
SQ Sequence 209 AA;

Query Match 51.3%; Score 504; DB 22; Length 209;
Best Local Similarity 55.2%; Pred. No. 1.2e-48;
Matches 90; Conservative 32; Mismatches 41; Indels 0; Gaps 0;

```
Qy      25 FYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFTDQHYRALQQLQRDLGPHHFNVLAF 84
           || |:  : :|: |||||:| ||||||||:|  ||::|  |::| :: || ||:||||
Db      47 fyafevkdakgrtvslekykgkvslvvnvasdcqltdrnylglkelhkefgpshfsvlaf 106

Qy      85 PCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAVTGTGAHPAFKYLAQTSGKEPTWNF 144
           ||||||: ||  :||:|||| : | |:||:| || : |:   |||::|  :| ||| |||
Db     107 pcnqfgeseprpskevesfarknygvtfpifhkikilgsegepafrflvdsskkeprwnf 166

Qy     145 WKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLILLKREDL 187
           ||||| |:|:||  | |   :| :|  | ||||::|: |:|||
Db     167 wkylvnpegqvvkfwrpeepievirpdiaalvrqviikkkedl 209
```

RESULT 13
AAM39735
ID AAM39735 standard; Protein; 209 AA.
XX
AC AAM39735;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 2880.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI58891.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 4; SEQ ID NO 2880; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 209 AA;

Query Match 51.3%; Score 504; DB 22; Length 209;
Best Local Similarity 55.2%; Pred. No. 1.2e-48;
Matches 90; Conservative 32; Mismatches 41; Indels 0; Gaps 0;

```
Qy      25 FYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFTDQHYRALQQLQRDLGPHHFNVLAF 84
           || |:  : :|: |||||:| ||||||||:|  ||::|  |::| :: || ||:||||
Db      47 fyafevkdakgrtvslekykgkvslvvnvasdcqltdrnylglkelhkefgpshfsvlaf 106

Qy      85 PCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAVTGTGAHPAFKYLAQTSGKEPTWNF 144
           ||||||: ||  :||:|||| : | |:||:| || : |:   |||::|  :| ||| |||
Db     107 pcnqfgeseprpskevesfarknygvtfpifhkikilgsegepafrflvdsskkeprwnf 166

Qy     145 WKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLILLKREDL 187
           ||||| |:|:||  | |   :| :|  | ||||::|: |:|||
Db     167 wkylvnpegqvvkfwrpeepievirpdiaalvrqviikkkedl 209
```

RESULT 14
AAM41521
ID AAM41521 standard; Protein; 217 AA.
XX
AC AAM41521;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 6452.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.

XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI60677.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 2; SEQ ID NO 6452; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 217 AA;

Query Match 51.3%; Score 504; DB 22; Length 217;
Best Local Similarity 55.2%; Pred. No. 1.3e-48;
Matches 90; Conservative 32; Mismatches 41; Indels 0; Gaps 0;

```
Qy      25 FYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFTDQHYRALQQLQRDLGPHHFNVLAF 84
           || |:  : :|: ||||||:| ||||||||:|  ||::|  |::| :: || ||:|||
Db      55 fyafevkdakgrtvslekykgkvslvvnvasdcqltdrnylglkelhkefgpshfsvlaf 114

Qy      85 PCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAVTGTGAHPAFKYLAQTSGKEPTWNF 144
           ||||||: ||  :||:|||| : | |:||:| || : |:   |||::|  :| ||| |||
Db     115 pcnqfgeseprpskevesfarknygvtfpifhkikilgsegepafrflvdsskkeprwnf 174

Qy     145 WKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLILLKREDL 187
           ||||| |:|:||  | |   :| :|  | ||||::|: |:|||
Db     175 wkylvnpegqvvkfwrpeepievirpdiaalvrqviikkkedl 217
```

RESULT 15
AAG20980
ID AAG20980 standard; Protein; 169 AA.
XX
AC AAG20980;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 23370.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.

PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 34.9%; Score 343; DB 21; Length 169;
Best Local Similarity 42.3%; Pred. No. 1.5e-30;
Matches 71; Conservative 24; Mismatches 65; Indels 8; Gaps 2;

```
Qy      17 ACAQQEQDFYDFKAVNIRGKLVSLEKYRGSVSLVVNVASECGFTDQHYRALQQLQRDLGP 76
           | : : :  |||   : :|  | |  |:| | |:|||||:|| |: :|  | ||
Db       2 aassepkslydftvkdakgndvdlsiykgkvllivnvasqcgltnsnytelaqlyekykg 61

Qy      77 HHFNVLAFPCNQFGQQEPDSNKEIESFACRTYSVSFPMFSKIAVTGTGAHPAFKYLAQTS 136
           | | :|||||||||| ||| :|:||  |||  :   :|:| |: | |  | | :|:|  :
Db      62 hgfeilafpcnqfgnqepgtneeivqfactrfkaeypifdkvdvngdkaapvykflkssk 121

Qy     137 ----GKEPTWNFWKYLVAPDGKVVGAWDPTVSVEEVRLQITALVRKLI 180
               |    ||| |:|| || ||  : || |     | |   |:||:
Db     122 gglfgdgikwnfakflvdkdgnvvdrfaptts----plsiekdvkkll 165
```

Search completed: August 23, 2002, 14:39:05
Job time: 82 sec